The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Mutual Fund

Creeping Acquisition Near ThresholdOwnership Changes View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹375.00

prior close

₹373.15

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-2.5%-0.2% vs market

Pharmaceuticals peers, median of 157sector-2.1%-0.6% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.0

15m

-0.0

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7-2.5-0.2-2.1-0.6

Next day

-2.7-3.5+0.8-3.4+0.7

-0.7-2.3+1.6-2.0+1.4

-2.1-4.0+1.9-3.4+1.3

-3.1-3.5+0.4-3.5+0.4

-1.3-1.9+0.6-3.2+1.9

-2.1-1.8-0.3-2.2+0.1

15d

+0.3+2.2-1.9+1.1-0.8

+2.4+0.2+2.2-1.8+4.2

+1.3-7.5+8.9-8.0+9.3

-4.8+0.7-5.4-0.1-4.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SBI Mutual Fund, through its various schemes, has bought a net 3.34 crore shares of Biocon, taking its total holding from 5.34% to 7.04% of the company's paid-up capital. The acquisition happened on January 16, 2026, through a mix of market purchase and Qualified Institutional Placement (QIP). SBI MF is not part of the promoter group. The previous disclosure under the same regulation was made in November 2025 when its holding stood at 5.00%. Biocon's total equity share capital also increased from ₹754 crore to ₹810 crore during this period, indicating fresh share issuance to institutional investors.

Likely market impact

This is a significant institutional buying signal, with a large domestic fund increasing its stake by over 2 percentage points in just two months. The continued accumulation by SBI MF along with the QIP-based capital raise suggests strong institutional confidence in Biocon, which is generally positive for stock sentiment. Existing shareholders should note that promoter holdings are not impacted as SBI MF is a non-promoter institutional investor.